Advisory Board

Advisory Board

Supporting great science

Outstanding experts make up CARB-X’s Advisory Board. The Advisory Board ensures the highest scientific standards in evaluating applications for CARB-X funding. Every member of the CARB-X Advisory Board completes a conflict-of-interest-process and is excluded from participation in the review or approval of any application with which they have a conflict of interest. We thank them sincerely for their work.

Rosemarie Aurigemma, PhD
Deputy Associate Director, Developmental Therapeutics, Program Division of Cancer Treatment and Diagnosis
National Cancer Institute, NIH

Ellen Jo Baron
Professor Emerita, Stanford University, Diagnostic Microbiology Development Program

Maureen J. Beanan, PhD
Program Officer, NIH/NIAID

Keith A. Bostian, PhD
CEO, Institute for Life Science Entrepreneurship

David Boucher, PhD
Health Scientist, ASPR/BARDA

Patricia A. Bradford, PhD
Antimicrobial DevelopmentSpecialists, LLC

Liliana Brown, PhD
Program Officer, Office of Genomics and Advanced Technologies, Division of Microbiology and Infectious Diseases/NIAID/NIH

Karen Bush, PhD
Professor of Practice in Biotechnology, Indiana University

Joseph Campbell, PhD
Program Officer, Research Resources Section, Office of Biodefense, Research Resources and Translational Research

Daniel Chelsky, PhD
CSO, Caprion Biosciences Inc.

Thomas Chen
Independent Consultant

Peter Coderre, PhD, MBA
Owner, Antimicrobial Regulatory Consulting LLC

R.D.G. Cooper D.Sc., PhD
Cooper Consulting LLC

Patrice Courvalin, MD, FRCP
Departement de Microbiologie, Institut Pasteur

Lloyd Czaplewski, PhD
Independent Consultant, Director at Abgentis

Thomas J. Dougherty, PhD
Dept. of Microbiology & Immunobiology, Harvard Medical School

Michael N. Dudley, PharmD, FIDSA
Senior Vice President, Head of R&D, Co-Lead, Infectious Disease Global Innovation, The Medicines Company

Ann E. Eakin, PhD
Senior Scientific Officer, DMID, NIAID/NIH

Paul Eder, PhD
Principal and Senior Medical Diagnostics Advisor, Tunnell Government Services, for BARDA

Sabiha Essack, B. Pharm., M. Pharm., PhD
South African Research Chair in Antibiotic Resistance & One Health, Professor of Pharmaceutical Sciences, University of KwaZulu-Natal

Ronnie Farquhar, D. Phil.
Morningside Ventures

Marta Fernandez Suarez
Independent Consultant, Life Sciences R&D and Global Health

Anthony Ford-Hutchinson, PhD
Independent Consultant to the Pharmaceutical Industry

Francois Franceschi, PhD
Program Officer, Bacteriology and Mycology Branch, NIH/NIAID

Humphrey Gardner, MD
Chief, Medical Oncology, Evelo Biosciences

Steven C. Gilman, PhD
Chairman and Chief Executive Officer, Contrafect Corporation

Alan Goldberg
Special Government Employee and SME Drug Development, BARDA/ ASPR/ HHS

Mark J. Goldberger, MD, MPH
Independent Consultant, Mark Goldberger MD, MPH LLC

Herman Goossens
Professor, University Hospital Antwerp

Howard B. Haimes, PhD
Subject Matter Expert, Translational Medicine DTRA

Raymond D. Harris, PhD
Program Officer, Office of Biodefense, Research Resources and Translational Research, DMID/NIAID/NIH

Deborah T. Hung, MD, PhD
Co-Director, Infectious Disease and Microbiome Program, Core Institute Member, Broad Institute of MIT and Harvard
Associate Professor, Department of Genetics, Harvard Medical School, Associate Professor, Department of Molecular Biology, Massachusetts General Hospital

Richard James
CEO, Developing Novel Antibiotics Consultancy

Randall Kincaid, PhD
Senior Scientific Officer Division of Microbiology and Infectious Diseases, NIAID/NIH

Jane M. Knisely, PhD
Program Officer, NIAID/NIH

Gerald R. Kovacs, PhD
Senior Adviser, CMI Consulting for BARDA

Marina Kozak, PhD
Health Scientist, Division of CBRN Countermeasures, BARDA/ASPR/HHS

John S. Lee, PhD
Health Scientist, Diagnostics and Medical Devices Division (DMD), BARDA/ASPR/HHS

Malen Link, PhD
Biologist, Division of CBRN Countermeasures, ASPR/HHS/BARD

Frederic J Marsik, PhD
Clinical Microbiology Consultant

Marielena Mata, PhD
Head of Precision Medicine and Companion Diagnostics, GSK

Chris Meda, MS
Chief Business Officer, IncellDx Inc., National Sponsorship Chair, Women in Bio, Board Director, Claremont BioSolution

Michael Merchlinsky, PhD
Scientific Program Manager, ASPR/BARDA

Linda A. Miller, PhD
Clinical Microbiologist, MID Pharma Consulting, LLC

Paul F. Miller, PhD
Chief Scientific Officer, Synlogic

Valerie Ng
Professor Emeritus, Department of Laboratory Medicine, School of Medicine, UCSF; and Chair, Laboratory Medicine & Pathology, Alameda Health System. Laboratory Director, Clinical Laboratories, Alameda Health System.

Tam Nguyen, PhD
Program Officer, NIAID

Sylvia A. Norman, PhD
President & CEO, Sandhill Crane Diagnostics Inc.

David Oldach, MD, FIDSA
Chief Medical Officer, Cempra Pharmaceuticals Inc.

Frederick B. Oleson, Jr., DSc
Independent Consultant

Sharon Peacock, MBBS, PhD, FRCP, FRCPath, FMedSci, CBE
Professor of Clinical Microbiology, London School of Hygiene andTropical Medicine
Non-executive Director, Addenbrooke’s Hospital, Cambridge

Steven J. Projan, PhD, F.A.A.M.
Sr. Vice President R&D, Innovative Medicines Head Infectious Disease & Vaccines, MedImmune

Ryan T. Ranallo, PhD
Program Officer, Division of Microbiology and Infectious Diseases, NIAID

George Risi, MD, MSc
Senior Medical Adviser, Division of Clinical Development, BARDA

Bill Rodriguez, MD
Managing Director, Draper Richards Kaplan Foundation

Dominic Ryan, PhD

Helen Schiltz, PhD
Program Officer, Drug Development Section, Office of BioDefense, Research Resources, and Translational Research, DMID/NIAID/NIH

Oxana A. Selivanova, PhD
Interdisciplinary Scientist, BARDA/ASPR

Karen Joy Shaw, PhD
CSO, Amplyx Pharmaceuticals
President, Hearts Consulting Group

Richard Seabrook, PhD, MBA
Independent Consultant
Senior Advisor, Translational R&D at Catapult

Anita Sheoran, PhD
Program Officer, Drug Development, Division of Microbiology & Infectious Diseases, NIAID

Nicola Shepherd, PhD
Director, Bellows Consulting Ltd.

David Shlaes
Anti-infectives Consulting, LLC, Retired

Lynn L. Silver, PhD
LL Silver Consulting, LLC

Jared A. Silverman, PhD
Senior Vice President, Research, Kaleido Biosciences

Keith Spencer, PhD
Director Academic Liaison, GSK

Katy Stein, PhD
Principal, Kathryn Stein Consulting

Jeff Stein, PhD
President & CEO, Cidara Therapeutics

Joyce Sutcliffe, PhD
Independent Antibacterial Consultant

Bob Suva
Independent Antibacterial Consultant

Kimberly L. Taylor, PhD
Project Officer, Vaccine Development Section, Office of Biodefense, Research Resources and Translational Research, DMID/NIAID

Fred C. Tenover, PhD D(ABMM)
Vice President, Scientific Affairs, Cepheid

Ursula Theuretzbacher, PhD
Antibiotic R&D expert, Center for Anti-Infective Agents

Brian N. Tse, PhD
Health Scientist, BARDA/ASPR/HHS

Mark Wilcox, MD, FRCPath
Professor of Medical Microbiology, University of Leeds
Consultant Microbiologist, Head of research and Development in Microbiology at Leeds Teaching Hospitals

Daniel Wolfe, PhD
Health Scientist, BARDA

Neil Woodford BSc PhD FRCPath
Professor, Head, Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit
National Infection Service, Public Health England

Lanling Zou, MD, PhD
Bacteriology Program Officer, Chief, Translational Sciences Section, BMB/DMID/NIAID/NIH/DHHS